Business Context and Reporting Period
This Form 8-K Current Report was filed by Propanc Biopharma, Inc. on January 11, 2021, covering events occurring on January 5, 2021. The Company, incorporated in Delaware with principal offices in Australia, is an emerging growth company trading on the OTC Pink market under the symbol PPCB. The filing discloses the entry into a material definitive agreement involving a private placement of debt securities.
Key Financial Metrics and Transaction Details
- Transaction Type: Issuance of an 8% Convertible Promissory Note.
- Principal Amount: $68,500.
- Net Proceeds: $65,000 (after deducting $3,500 in fees and expenses paid to the investor).
- Use of Proceeds: General working capital purposes.
- Interest Rate: 8% per annum, payable in cash or shares of common stock upon maturity or acceleration.
- Maturity Date: January 5, 2022.
- Conversion Terms: Convertible at the investor's option starting July 5, 2021, at a "Variable Conversion Price" equal to 65% of the Market Price (a 35% discount).
- Conversion Cap: Investor is restricted from converting if it would result in beneficial ownership exceeding 4.99% of outstanding shares.
Material Changes and Prepayment Provisions
The filing details a significant change in the Company's capital structure through the addition of convertible debt. The Note includes a tiered prepayment premium schedule if the Company chooses to prepay within 180 days of issuance:
- Prepayment within 60 days: 110% of face amount plus accrued interest.
- Prepayment between 61-90 days: 115% of face amount plus accrued interest.
- Prepayment between 91-120 days: 120% of face amount plus accrued interest.
- Prepayment between 121-150 days: 125% of face amount plus accrued interest.
- Prepayment between 151-180 days: 129% of face amount plus accrued interest.
The filing does not provide comparative financial metrics (revenue, profit, cash flow) for the period, as this is a transaction-specific report rather than a periodic financial statement.
Outlook, Risks, and Contingencies
Default Provisions: Upon the occurrence of certain events of default (including failure to issue shares upon conversion, insolvency, or failure to maintain OTC listing), the Note becomes immediately due and payable. The Company must pay a "Default Amount" equal to 150% of the outstanding principal plus accrued interest.
Penalties: A penalty of $1,000 is incurred if the Company fails to deliver shares upon conversion within three business days of notice, unless the failure is due to a third party (e.g., transfer agent).
Covenants: The Company covenants not to sell or dispose of substantially all assets outside the ordinary course of business without investor consent, which would render the Company a "shell company."
Risks: The conversion mechanism includes a 35% discount to the market price, which may result in significant dilution to existing shareholders. The Company must maintain at least five times the number of shares issuable upon full conversion in reserve.
Investor Verification Checklist
- Verify the current share count to assess the potential dilution impact of the 35% discount conversion feature.
- Confirm the Company's ability to maintain its OTC listing status to avoid triggering an event of default.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Convertible Promissory Note (Exhibit 4.1) for additional covenants not summarized here.
- Monitor the Company's cash position to ensure it can meet the 8% interest obligation or the potential 150% default payment if liquidity issues arise.
- Check for any subsequent filings regarding the actual closing date (stated as "on or about January 7, 2021") and the issuance of shares if conversion occurs.